Indaptus Therapeutics, INC 8-K filings

Indaptus Therapeutics has partnered with BeiGene to evaluate the combination of Decoy20 and tislelizumab in a clinical trial for advanced solid tumors, with the study anticipated to begin in 2025.

Indaptus Therapeutics reported its second quarter 2024 financial results, highlighted clinical trial progress, and announced a recent $3 million capital raise.

Indaptus Therapeutics has announced a $3 million capital raise through a registered direct offering and concurrent private placement to fund research and development.

Indaptus Therapeutics' stockholders approved an amended stock incentive plan and elected three Class III directors at their 2024 annual meeting.

Indaptus Therapeutics has successfully dosed the first patient in the multi-dose portion of its Phase I trial for Decoy20 after a positive safety review, with plans to explore combination studies with a checkpoint inhibitor.

Indaptus Therapeutics announced its first quarter 2024 financial results, highlighting a decrease in operating expenses and progress in clinical development.

Indaptus Therapeutics will present new data on its research compound, Decoy10, at the 2024 AACR Annual Meeting, demonstrating its ability to activate multiple immune cell types involved in anti-tumor responses.

Indaptus Therapeutics reported positive results from the second cohort of its Phase 1 trial for Decoy20 and provided a financial update for the year ended December 31, 2023.

Indaptus Therapeutics reports positive results from the second cohort of its Phase 1 trial for Decoy20, showing a broad immune response and prompting the start of multi-dose patient screening.

Indaptus Therapeutics has updated its bylaws to comply with universal proxy rules and streamline procedures for stockholder nominations and proposals.